Methods for restoring lysosomal function in retinal pigment epithelial cells by activating TFEB
By administering nucleic acid or polypeptide encoding a TFEB polypeptide to the subject, and using AAV vector to restore the lysosomal function of retinal pigment epithelial cells, the AMD treatment problem in the prior art is solved, and effective treatment and prevention of diseases such as AMD are achieved.
Patent Information
- Application Number
- CN202080077429.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-09
- Filing Date
- 2020-03-06
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-03-06
AI Technical Summary
The prior art cannot effectively treat and prevent age-related macular degeneration (AMD), especially atrophic AMD, and existing treatments are expensive and cannot function for a long time, and there is a lack of targeted treatments for early-stage diseases.
Transfection is performed using AAV vectors by administering to the subject to a nucleic acid or polypeptide encoding a transcription factor EB (TFEB) polypeptide containing a constitutively active form to restore lysosomal function of retinal pigment epithelial cells and alleviate the AMD-like phenotype.
Achieving the recovery of retinal pigment epithelial cells, reducing AMD-like phenotype, providing treatment and prevention means for AMD, Stargardt macular retinal degeneration, neurodegenerative diseases and diabetic retinopathy, demonstrating potential treatment for these diseases Effect.
Smart Images

Figure CN114828857B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This patent application claims the benefit of U.S. Provisional Patent Application No. 62 / 897,800, filed on September 9, 2019, which is incorporated herein by reference.
[0003] Sequence Listing
[0004] Incorporated herein by reference in its entirety is the Nucleotide / Amino Acid Sequence Listing filed concurrently herewith. Background Art
[0005] Age-related macular degeneration (AMD) is the world’s leading cause of blindness among older adults. The number of people with AMD is expected to reach 196 million in 2020 and increase to 288 million by 2040. More than 15 million Americans are affected by AMD, and the cost of treatment exceeds $350 billion. The latest data indicates that by 2020, more than 3 million more people in the United States will be diagnosed with the disease.
[0006] The vast majority of patients suffer from atrophic (dry) AMD. However, due to the relentless progression of the disease, they will develop advanced disease within 10 years. As the "baby boomer" generation ages, the burden of dry AMD is increasing. Despite the growing number of affected individuals, there is currently no definitive treatment (other than the AREDS II formulation for moderate AMD) or preventive measures for dry AMD. Dry AMD affects approximately 80-90% of individuals with the disease. Its cause is unknown, and it generally progresses more slowly than the wet form.
[0007] There are currently anti-VEGF therapies available for patients with wet AMD, such as AVASTIN TM (bevacizumab), LUCENTIS TM (ranibizumab injection) and EYLEA TM (aflibercept). However, the treatment regimen (which requires monthly injections) is very expensive, does not work long-term, and does not help all patients.
[0008] Due to the large number of patients suffering from atrophic AMD, new treatment approaches are needed that target the disease early, before vision loss. Summary of the invention
[0009] The present invention provides a method for restoring the lysosomal function of retinal pigment epithelial (RPE) cells, comprising administering to a subject in need thereof (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of transcription factor EB (TFEB) or (ii) the polypeptide. The nucleic acid may be contained in a vector (e.g., an AAV vector).
[0010] The subject (e.g., mankind) may suffer from age-related macular degeneration (AMD) or have the risk of developing AMD, wherein AMD may be wet AMD or atrophic (dry) AMD, which may include map-like atrophy. The subject may suffer from Stargardt macular retinal degeneration or have the risk of developing Stargardt macular retinal degeneration. The subject may suffer from a neurodegenerative disease (such as Alzheimer's disease or Parkinson's disease) or have the risk of developing a neurodegenerative disease. Alternatively or additionally, the subject may suffer from diabetic retinopathy (DR) or have the risk of developing DR.
[0011] Therefore, the present invention provides a method for preventing and / or treating AMD, Stargardt macular retinal degeneration, neurodegenerative diseases or diabetic retinopathy in a subject, the method comprising administering to the subject (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of transcription factor EB (TFEB) or (ii) the polypeptide. The nucleic acid may be contained in a vector (e.g., an AAV vector).
[0012] The polypeptide may comprise the amino acid sequence of SEQ ID NO: 1, except that the serine at one or more of positions 138, 142, 211, 455, 462, 463, 466, 467 and 469 of SEQ ID NO: 1 is independently substituted with another amino acid. Specifically,
[0013] (i) the serine at position 138 of SEQ ID NO: 1 may be substituted with alanine, and / or
[0014] (ii) the serine at position 142 of SEQ ID NO: 1 may be substituted with alanine, and / or
[0015] (iii) the serine at position 211 of SEQ ID NO: 1 may be substituted with alanine, and / or
[0016] (iv) the serine at position 455 of SEQ ID NO: 1 may be substituted with alanine, and / or
[0017] (v) the serine at position 462 of SEQ ID NO: 1 may be substituted with aspartic acid, and / or
[0018] (vi) the serine at position 463 of SEQ ID NO: 1 may be substituted with aspartic acid, and / or
[0019] (vii) the serine at position 466 of SEQ ID NO: 1 is substituted with aspartic acid, and / or
[0020] (viii) the serine at position 467 of SEQ ID NO: 1 is substituted with alanine, and / or
[0021] (ix) The serine at position 469 of SEQ ID NO: 1 is substituted with aspartic acid.
[0022] In one embodiment, the polypeptide may comprise the amino acid sequence of SEQ ID NO: 1, except that the serine at each of positions 138, 142 and 211 of SEQ ID NO: 1 is substituted with alanine, respectively.
[0023] In another embodiment, the polypeptide may comprise the amino acid sequence of SEQ ID NO: 1, except that the serine at position 455 of SEQ ID NO: 1 is substituted with alanine, and optionally, the serine at position 211 of SEQ ID NO: 1 is substituted with alanine.
[0024] In another embodiment, the polypeptide may comprise the amino acid sequence of SEQ ID NO: 1, except that the serine at each of positions 462, 463, 466 and 469 of SEQ ID NO: 1 is substituted with aspartic acid, respectively, and the serine at position 467 of SEQ ID NO: 1 is substituted with alanine.
[0025] The present invention also provides (a) a pharmaceutically acceptable carrier and (b) a polypeptide, a nucleic acid encoding the polypeptide, or a vector comprising the nucleic acid.
[0026] The present invention further relates to a pharmaceutical composition for preventing and / or treating AMD (e.g., atrophic AMD or wet AMD), Stargardt macular degeneration, a neurodegenerative disease (e.g., Alzheimer's disease or Parkinson's disease) or diabetic retinopathy, comprising (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of TFEB or (ii) the polypeptide.
[0027] The present invention relates to (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of TFEB or (ii) the use of said polypeptide in the preparation of a pharmaceutical composition for preventing and / or treating AMD (e.g., atrophic AMD or wet AMD), Stargardt macular retinal degeneration, a neurodegenerative disease (e.g., Alzheimer's disease or Parkinson's disease) or diabetic retinopathy.
[0028] The present invention relates to (i) nucleic acids encoding polypeptides comprising a constitutively active form of TFEB or (ii) use of said polypeptides for preventing and / or treating AMD (e.g., atrophic AMD or wet AMD), Stargardt macular retinal degeneration, neurodegenerative diseases (e.g., Alzheimer's disease or Parkinson's disease) or diabetic retinopathy.
[0029] The present invention also relates to (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of TFEB or (ii) said polypeptide for use in preventing and / or treating AMD (e.g., atrophic AMD or wet AMD), Stargardt macular retinal degeneration, a neurodegenerative disease (e.g., Alzheimer's disease or Parkinson's disease), or diabetic retinopathy. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figures 1A-1C A 78-year-old male control ( Figure 1A ) and an 84-year-old man with atrophic AMD ( Figure 1B ) of the RPE / choroid. In control eyes, strong TFEB immunoreactivity was prominent in the RPE nuclei (arrows), but not in ( Figure 1B ) is absent in the RPE nucleus of AMD eyes (asterisk), as shown in ( Figure 1C ). Note: (B) shows multi-layer RPE. Bar = 20 μm; *P < 0.05.
[0031] Figure 2A-2B It was shown that expression of proteins in the endocytic pathway is reduced in RPE cells from Cryba1 conditional knockout (cKO) mice (Cryba1 is specifically deleted from RPE cells as described in Valapala et al., Nat. Commun., 4:1629 (2013)). Figure 2A As shown by Western blot (WB), the floxed control (Cryba1 fl / fl Rab5 (an early endosomal marker) was reduced in 5-month-old Cryba1 cKO RPE cells compared to 5-month-old Cryba1 cKO RPE cells (as described in Valapala et al., Sci. Rep. 5:8755 (2015)). Actin was used as an internal control. The figure shows mean ± SD and *P < 0.05 (two-tailed t-test), n = 5. Figure 2B Display, as shown by WB, with Cryba1 fl / flEEA1, a protein required for fusion of primary and secondary endosomes and sorting at the level of primary endosomes, and APPL1, which regulates vesicle trafficking and endosomal signaling, were reduced in 5-month-old Cryba1 cKO RPE cells compared to RPE cells. Actin was used as an internal control.
[0032] Figures 3A-3C These results suggest that Cryba1 cKO mice exhibit RPE cell heterogeneity. Figure 3A Immunostaining of EBP50 on retinal sections of 1-month-old and 9-month-old cKO mice is shown, demonstrating a reduction in EBP50 and microvilli length in RPE cells compared to controls. Figure 3B It was shown that RPE extracts from 3-month-old mice had reduced expression of apical proteins (ERM and EBP50) in cKO RPE cells. Figure 3C 4-month-old Cryba1 cKO mouse RPE flat-mount image, which shows the RPE heterogeneity as visualized using phalloidin (F-actin) and EBP50 (microvilli) antibodies. Both F-actin and EBP50 staining show the area of cell loss on the apical side in cKO RPE (arrows). As the mice age, the pockets of cell loss are more severe (not shown). Orthogonal images (merge / orthogonal) show the shedding of RPE microvilli (arrows). Bar = 20 mm. The figure shows mean ± SD and *P < 0.05, **P < 0.01 (two-tailed t-test), n = 5.
[0033] Figure 4 The clathrin-mediated endocytosis of the changes in the RPE cells from Cryba1 cKO mice is shown. Live cell imaging was performed using a total internal reflection fluorescence (TIRF) microscope to the clathrin-mediated endocytosis from the apical side of floxed control and cKO RPE cells. RPE-choroid-sclera complexes were cultured in glass bottom culture dishes and infected with rAVCMV-LifeAct-TagGFP2 and Ad-CMV-FAP-mClta to show actin and clathrin, respectively. Flat-mounted TIRF images and / or videos were taken on an inverted Nikon Ti using Plan Apo TIRF 1.49NA 100x oil objective and Prime 95b camera (Photometrics). More than 12 seconds, clathrin vesicles failed to enter the apical plasma membrane (arrow), and insertion occurred in the floxed control.
[0034] Figure 5 is a schematic diagram of the WT-TFEB and constitutively active TFEB-S210A preparations described in the Examples.
[0035] Figure 6A-6C shows that AAV2-TFEB vector is suitable for transfection in RPE cells. (A) RPE / choroid from uninfected mice and (B) RPE / choroid after subretinal injection of AAV2-TFEB-GFP demonstrated effective infection of more than 85-90% of RPE cells after a single subretinal infection. No cells expressing GFP were found in the neurosensory retina or choroid (not shown). (C) Peak expression was observed after 7 days. Similarly, no cells expressing GFP were found in the neurosensory retina or choroid two weeks after infection (not shown).
[0036] Figures 7A-7C is a diagram illustrating that restoring TFEB function alleviates changes in lysosomal function and autophagy in RPE cells of Cryba1 KO mice. Fig. 7A The authors describe the administration of constitutively active mouse TFEB (TFEB) to RPE cells of Cryba1 KO mice. S210A ) of AAV vectors leading to TFEB S210A Translocates to the nucleus of RPE cells. Figure 7B Figure 2 shows the difference between Cryba1 KO mice expressing TFEB and wild-type mice (1), Cryba1 KO mice without vector (2), and Cryba1 KO mice administered with AAV vector expressing wild-type TFEB (3). S210A A graph showing the relative expression of CTSB, LAMP2, ATP6VOA1, and CTSD in RPE cells of Cryba1KO mice (4) infected with AAV vectors. Figure 7C Figure 3 shows the expression of p62 / SQSTM1 in RPE cells of Cryba1 KO mice infected with AAV vector expressing TFEB compared with that in RPE cells of Cryba1 KO mice infected with AAV vector expressing wild-type TFEB. S210A Relative expression in RPE cells of Cryba1 KO mice infected with AAV vectors of . Empty AAV had no effect. Mean ± SD, n = 3. P values were evaluated by one-way AVOVA and Tukey's post-hoc test and are representative of at least 3 independent experiments. *P < 0.05 and **P < 0.01.
[0037] Figures 8A-8C Iron accumulation and inflammasome activation in RPE cells of aged Cryba1 cKO mice are shown. Fig. 8A showed that iron overload due to lysosomal abnormalities in RPE cells may lead to inflammasome activation and cell death. Figure 8B Shown are the differences between 4-month (1, 2) or 10-month (5, 6) Cryba1 mice under fed and starved conditions. fl / flCompared with Cryba1 cKO mice (control), the levels of redox-sensitive ferrous ions were increased in RPE cells of Cryba1 cKO mice at 4 months (3, 4) or 10 months (7, 8). Figure 8C showed that the levels of inflammasome markers NLRP3 and cleaved caspase-1 were elevated in RPE cells of aged Cryba1 cKO mice compared with age-matched controls.
[0038] Figures 9A-9C showed that TFEB activation alleviated iron accumulation and inflammasome activation in Cryba1 KO RPE cells in vitro. Fig. 9A The results show that in the presence of the iron chelator lipocalin-2 (LCN-2) and the iron source ferric ammonium citrate (FAC), cells expressing constitutively active mouse TFEB (TFEB S210A ) were administered to Cryba1 KO RPE cells. Figure 9B-9C Compared with Cryba1 KO RPE cells infected with AAV vector expressing wild-type TFEB, S210A AAV vector infection of Cryba1 KO RPE cells can reverse iron accumulation and inflammasome activation (increased NLRP3 and IL-β expression). *P<0.05 and **P<0.01. Figures 10A-10B The results showed that restoring TFEB function alleviated the changes in lysosomal function and autophagy in RPE cells of Cryba1 cKO mice. Nine-month-old Cryba1 cKO mice were subretinal injected with an AAV vector expressing WT TFEB (WT TFEB vector) or expressing constitutively active mouse TFEB (TFEB vector). S210A )(mutated TFEB vector). Fig. 10A It is shown that administration of the mutant vector to RPE cells of Cryba1 cKO mice resulted in the reactivation of CLEAR (Coordinated Lysosomal Expression and Regulation) network genes by qPCR. Fig. 10B It is shown that administration of mutant vectors to Cryba1 cKO mice resulted in increased autophagosome clearance in RPE cells, with decreased cellular p62 / SQSTM1 levels. Animals were sacrificed two months later, and RPE-choroid complexes were harvested. *P<0.05, **P<0.01 (n=4).
[0039] Figures 11A-11B Shows that relative to Cryba1 fl / fl Control, most cytosolic sequestration of TFEB in RPE cells from fasted and fed Cryba1 KO mice ( Fig.11A ), accompanied by a decrease in CLEAR network genes in RPE cells from Cryba1 cKO mice ( Fig. 11B).
[0040] Figures 12A-12B Shown relative to Cryba1 fl / fl Lysosomal pH in RPE cells of control, Cryba1 cKO mice. Fig. 12A Graph showing that lysosomal pH was significantly increased in RPE cells of Cryba1 cKO mice relative to controls. Fig. 12B is a graph showing that overexpression of Cryba1 (by administration of pCDNA-Cryba1) in cKO RPE cells in vitro rescues pH abnormality.
[0041] Figures 13A-13B Shown relative to Cryba1 fl / fl Cathepsin D enzyme activity in RPE cells of control, Cryba1 cKO mice. Fig.13A To show the relative fl / fl Figure 3 shows the significant decrease in cathepsin D enzyme activity in RPE cells of control and Cryba1 cKO mice. Fig. 13B is a graph showing that overexpression of Cryba1 (by administration of pCDNA-Cryba1) in cKO RPE cells in vitro rescues cathepsin D enzymatic activity.
[0042] Figures 14A-14C Abnormalities in Cryba1 knockout mice were shown. Fig.14A The localization of [beta]A3 / A1-crystallin is shown in the lysosomal luminal fraction (fraction 1), with minimal expression in the lysosomal membrane fraction (fraction 2). Fig. 14B Cryba1 (encoding βA3 / A1-crystallin) conditional (deleted specifically from the RPE) and knockout mice (Cryba1 cKO) are shown. Fig. 14C Schematic diagram showing the development of RPE abnormalities and AMD-like phenotypes in Cryba1 cKO mice from 2-3 weeks to 9 months of age.
[0043] Figures 15A-15B Shown are autophagosome and autolysosome formation in Cryba1 cKO RPE cells. Fig.15A Shown are live cell imaging of RPE cells isolated from WT or cKO mice and transfected with a pH-sensitive reporter gene (mCherry-GFP-LC3), which shows that the formation of autophagolysosomes is reduced in Cryba1 cKO RPE cells relative to controls, which is rescued upon Cryba1 overexpression. Fig. 17B Quantification of the number of autophagosomes and autolysosomes spots under different conditions is shown.
[0044] Figures 16A-16BCathepsin D levels in WT and Cryba1 KO RPE cells are shown. Immunofluorescence ( Fig.16A ) and Western blot ( Fig. 16B ) shows that cathepsin D levels are reduced in RPE cells from Cryba1 KO mice compared to age-matched controls.
[0045] Figures 17A-17B These results suggest that Cryba1 KO mice display an age-related macular degeneration-like phenotype. Fig.17A is an immunofluorescence image of an RPE flat mount, showing the loss of the cobblestone-like structure of RPE cells (arrows) and a significant decrease in the expression of RPE65, a known marker for RPE cells. Fig. 17B are electron microscopy images showing accumulation of macrovacuoles (arrows) and basal layer deposits (asterisks and insets) in RPE cells of Cryba1 KO mice with age.
[0046] Fig.18A -C shows that the RPE of Cryba1 cKO mice retains (auto)phagosomes. Electron microscopy images show the accumulation of a large number of autophagosomes ( Fig.18A -arrows in B), these autophagosomes are loaded with photoreceptor outer segments and are not degraded ( Fig.18C ). DETAILED DESCRIPTION
[0047] The inventors found that an active form of TFEB can rejuvenate the function of RPE cells and rescue the AMD-like phenotype. This concept is also of great significance beyond AMD and provides unique insights into aging, age-related and neurodegenerative diseases, in which lysosomal dysfunction and cellular heterogeneity are important pathophysiological features.
[0048] The present invention provides a method for restoring lysosomal function of retinal pigment epithelial (RPE) cells, comprising administering to a subject in need thereof (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of TFEB or (ii) the polypeptide. The present invention also provides related polypeptides, nucleic acids, vectors and compositions.
[0049] The subject refers to a human or other animal (eg, a mammal such as a mouse, rat, guinea pig, hamster, cat, dog, rabbit, pig, cow, horse or primate), wherein the subject may refer to an animal (eg, a human) in need of prevention or treatment of a disease.
[0050] In one embodiment, the subject suffers from age-related macular degeneration (AMD) or has the risk of developing AMD.AMD can be wet AMD or atrophic (dry) AMD.The subject may suffer from a map-like atrophy secondary to AMD.Therefore, the present invention also provides a method for treating and / or preventing AMD in a subject.
[0051] In one embodiment, the subject suffers from or is at risk of developing Stargardt's macular retinal degeneration.Therefore, the present invention also provides a method for treating and / or preventing Stargardt's macular retinal degeneration.
[0052] In another embodiment, the subject suffers from or is at risk of developing a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease. Therefore, the present invention also provides a method for treating and / or preventing a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease in a subject.
[0053] In other embodiments, the subject suffers from diabetic retinopathy (DR) or is at risk of developing DR. The subject may also suffer from diabetic macular edema (DME) or is at risk of developing DME. Therefore, the present invention also provides a method for treating and / or preventing DR or DME in a subject.
[0054] Thus, the present invention provides a method of treating and / or preventing AMD, Stargardt macular degeneration, a neurodegenerative disease or diabetic retinopathy in a subject, comprising administering to the subject (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of TFEB or (ii) said polypeptide.
[0055] The polypeptide may comprise, consist essentially of, or consist of the amino acid sequence of SEQ ID NO: 1, except that the serine at one or more (e.g., two, three, four, five, six, seven, eight, or nine) of positions 138, 142, 211, 455, 462, 463, 466, 467, and 469 of SEQ ID NO: 1 is independently substituted with another amino acid (i.e., a naturally or non-naturally occurring amino acid other than serine). For example:
[0056] (i) the serine at position 138 of SEQ ID NO: 1 may be substituted with alanine, and / or
[0057] (ii) the serine at position 142 of SEQ ID NO: 1 may be substituted with alanine, and / or
[0058] (iii) the serine at position 211 of SEQ ID NO: 1 may be substituted with alanine, and / or
[0059] (iv) the serine at position 455 of SEQ ID NO: 1 may be substituted with alanine, and / or
[0060] (v) the serine at position 462 of SEQ ID NO: 1 may be substituted with aspartic acid, and / or
[0061] (vi) the serine at position 463 of SEQ ID NO: 1 may be substituted with aspartic acid, and / or
[0062] (vii) the serine at position 466 of SEQ ID NO: 1 is substituted with aspartic acid, and / or
[0063] (viii) the serine at position 467 of SEQ ID NO: 1 is substituted with alanine, and / or
[0064] (ix) The serine at position 469 of SEQ ID NO: 1 is substituted with aspartic acid.
[0065] In one embodiment, the polypeptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1, except that the serine at each of positions 138, 142, and 211 of SEQ ID NO: 1 is substituted with alanine, respectively.
[0066] In another embodiment, the polypeptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1, except that the serine at position 455 of SEQ ID NO: 1 is substituted with alanine, and optionally, the serine at position 211 of SEQ ID NO: 1 is substituted with alanine. Thus, the present invention provides (i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, except that the serine at position 455 of SEQ ID NO: 1 is substituted with alanine, and (ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, except that the serine at each of positions 211 and 455 of SEQ ID NO: 1 is substituted with alanine, respectively.
[0067] In additional embodiments, the polypeptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1, except that the serine at each of positions 462, 463, 466 and 469 of SEQ ID NO: 1 is substituted with aspartic acid, respectively, and the serine at position 467 of SEQ ID NO: 1 is substituted with alanine.
[0068] The polypeptides can be prepared by any of a variety of conventional techniques. In this regard, the polypeptide sequence can be synthetic, recombinant, isolated and / or purified.
[0069] The polypeptide can be isolated or purified from a recombinant source. For example, a DNA fragment encoding the desired polypeptide can be subcloned into a suitable vector using well-known molecular genetic techniques. The fragment can be transcribed and the polypeptide subsequently translated in vitro. Commercially available kits can also be used. The polymerase chain reaction can optionally be used for the manipulation of nucleic acids.
[0070] It is also possible to use an automatic peptide synthesizer to synthesize polypeptides according to methods known in the art. Alternatively, polypeptides can be synthesized using standard peptide synthesis techniques well known to those skilled in the art. Specifically, a solid phase synthesis procedure can be used to synthesize polypeptides. If desired, this can be accomplished using an automatic peptide synthesizer. The removal of tert-butyloxycarbonyl (t-BOC) or 9-fluorenylmethoxycarbonyl (Fmoc) amino acid blocking groups and the separation of polypeptides from resins can be achieved by, for example, acid treatment at a reduced temperature. The protein-containing mixture can then be extracted, for example, with ether to remove non-peptide organic compounds, and the synthesized polypeptide can be extracted from the resin powder (for example, with about 25% w / v acetic acid). After polypeptide synthesis, further purification (for example, using HPLC) can be optionally performed to eliminate any incomplete protein, polypeptide, peptide or free amino acid. The synthesized polypeptide can be subjected to amino acid and / or HPLC analysis to verify its characteristics. For other applications according to the present invention, it may be preferred to produce a polypeptide as a part of a larger fusion protein by chemical conjugation or by genetic means as known to those skilled in the art. In this regard, the present invention also provides a fusion protein comprising a polypeptide and one or more other proteins having any desired properties or functions to facilitate the isolation, purification, analysis or stability of the fusion protein.
[0071] The present invention also provides a kind of nucleic acid encoding this polypeptide.As used herein, " nucleic acid " includes " polynucleotide ", " oligonucleotide " and " nucleic acid molecule ", and generally refers to the polymer of DNA or RNA, it can be single-stranded or double-stranded, synthetic or obtain from natural source (for example, separation and / or purification), it can contain natural, non-natural or change nucleotide, and it can contain natural, non-natural or change internucleotide bond, for example phosphoramide bond or thiophosphate bond, rather than the phosphodiester found between the nucleotide of unmodified oligonucleotide.Generally preferably, nucleic acid does not comprise any insertion, deletion, inversion and / or replacement.However, as discussed herein, it may be suitable that nucleic acid comprises one or more insertion, deletion, inversion and / or replacement in some cases.
[0072] In one embodiment, the nucleic acid is recombinant. As used herein, the term "recombinant" refers to (i) a molecule constructed outside a living cell by joining a natural or synthetic nucleic acid segment to a nucleic acid molecule that can replicate in a living cell, or (ii) a molecule obtained by replication of the molecule described in (i) above. For purposes of this article, replication can be in vitro replication or in vivo replication.
[0073] Nucleic acid (e.g., DNA, RNA, cDNA, etc.) can be produced in any suitable manner, including but not limited to recombinant production and commercial synthesis. In this regard, the nucleic acid sequence can be synthetic, recombinant, isolated and / or purified.
[0074] Nucleic acids can be constructed based on chemical synthesis and / or enzyme ligation reactions using procedures known in the art. See, for example, Green et al. (eds.), Molecular Cloning, A Laboratory Manual, 4th edition, Cold Spring Harbor Laboratory Press, New York (2012). For example, naturally occurring nucleotides or differently modified nucleotides (e.g., thiophosphate derivatives and acridine substituted nucleotides) can be used to chemically synthesize nucleic acids, and the differently modified nucleotides are designed to increase the biological stability of the molecule or increase the physical stability of the duplex formed during hybridization. The embodiments of the modified nucleotides that can be used to produce nucleic acids include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyl uracil, dihydrouracil, β-D-galactoside, inosine, N 6 -Isopentenyl adenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N 6 -substituted adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, β-D-mannosylquinine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N 6-isopentenyl adenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, quinine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methyl ester, 3-(3-amino-3-N-2-carboxypropyl) uracil and 2,6-diaminopurine. Alternatively, one or more nucleic acids of the present invention can be purchased from companies such as Macromolecular Resources (Fort Collins, CO) and Synthegen (Houston, TX).
[0075] The nucleic acid of coded polypeptide can be provided as a part of construct, and the construct comprises the nucleic acid and the element that can deliver the nucleic acid to cell and / or express the nucleic acid in cell.For example, the polynucleotide sequence of coded polypeptide can be operably connected with expression control sequence.Connect the expression control sequence operably connected with coding sequence, so that the expression of coding sequence is realized under the condition compatible with expression control sequence.Expression control sequence includes but is not limited to suitable promoter, enhancer (for example, CMV enhancer), transcription terminator, the start codon (that is, ATG) in front of the gene of coded protein, the splicing signal of intron, the correct reading frame of maintaining the gene to allow the correct translation of mRNA, and termination codon.Suitable promoter includes but is not limited to hVMD2 promoter, SV40 early promoter, RSV promoter, adenovirus major late promoter, people CMV immediate early I promoter, poxvirus promoter, 30K promoter, I3 promoter, sE / L promoter, 7.5K promoter, 40K promoter and C1 promoter.
[0076] Nucleic acids encoding polypeptides can be cloned or amplified by in vitro methods, such as polymerase chain reaction (PCR), ligase chain reaction (LCR), transcription-based amplification system (TAS), self-sustaining sequence replication system (3SR) and Qβ replicase amplification system (QB). For example, polynucleotides encoding polypeptides can be isolated by polymerase chain reaction of cDNA using primers based on the DNA sequence of the molecule. Various cloning and in vitro amplification methods are well known to those skilled in the art.
[0077] The invention provides a vector comprising the nucleic acid. The nucleic acid can be inserted into any suitable vector. The selection of vectors and methods for constructing them are well known in the art and described in general technical references.
[0078] Suitable vectors include those designed for propagation and expansion or for expression or both. Examples of suitable vectors include, for example, plasmids, plasmid-lipid complexes, CELid vectors (see, for example, Li et al., PLoS One, 8(8): e69879.doi: 10.1371 / journal.pone.0069879 (2013)) and viral vectors, such as parvovirus-based vectors (i.e., AAV vectors), retroviral vectors, herpes simplex virus (HSV)-based vectors, adenovirus-based vectors, and poxvirus vectors. Any of these expression constructs can be prepared using standard recombinant DNA techniques.
[0079] In one aspect of the present invention, carrier is a viral vector, such as an AAV carrier. The AAV carrier can be suitable for packaging into any AAV serotype or its variant, which is suitable for application to eye cells (e.g., RPE cells). The embodiment of suitable AAV serotypes can include but is not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, its variant, and engineered or newly synthesized AAV viruses, such as AAV.7m8.
[0080] The AAV vector may be packaged in a capsid protein or fragment thereof of any AAV serotype described herein. Preferably, the vector is packaged in an AAV2 capsid.
[0081] Suitable recombinant AAV can be produced by culturing packaging cells, which contain nucleic acid sequences encoding AAV serotype capsid proteins or fragments thereof as defined herein; functional rep genes; any of the vectors of the invention as described herein; and sufficient auxiliary functions to allow the vectors of the invention to be packaged into AAV capsid proteins. The components required for packaging the AAV vectors of the invention in AAV capsids by packaging cells can be provided to host cells in trans. Alternatively, any one or more required components (e.g., vectors of the invention, rep sequences, capsid sequences, and / or auxiliary functions) can be provided by stable packaging cells that have been engineered to include one or more required components using methods known to those skilled in the art.
[0082] In one embodiment of the present invention, the AAV vector is self-complementary. Self-complementary vectors can advantageously overcome the rate-limiting step of second strand DNA synthesis and confer earlier onset and more robust gene expression.
[0083] In one embodiment of the present invention, the vector is a recombinant expression vector. For the purposes of this article, the term "recombinant expression vector" means a genetically modified oligonucleotide or polynucleotide construct, when the construct comprises a nucleotide sequence encoding mRNA, protein, polypeptide or peptide, and the vector is in contact with the cell under conditions sufficient to allow mRNA, protein, polypeptide or peptide to be expressed in the cell, the construct allows the host cell to express mRNA, protein, polypeptide or peptide. The vector of the present invention is generally not naturally occurring. However, the part of the vector may be naturally occurring. The recombinant expression vector of the present invention may include any type of nucleotides, including but not limited to DNA and RNA, which may be single-stranded or double-stranded, synthetic or partially obtained from natural sources, and they may include natural, non-natural or altered nucleotides. The recombinant expression vector may include naturally occurring, non-natural internucleotide bonds, or two types of bonds. Preferably, non-naturally occurring or altered nucleotides or internucleotide bonds do not hinder the transcription or replication of the vector.
[0084] Vectors can be prepared using standard recombinant DNA techniques such as those described above by Green et al. Circular or linear expression vector constructs can be prepared to contain replication systems that function in prokaryotic or eukaryotic host cells. The replication system can be derived from, for example, ColE1, 2μ plasmid, lambda, SV40 virus, bovine papilloma virus, etc.
[0085] In addition to the nucleic acid encoding the polypeptide, the vector can also contain one or more nucleic acid sequences encoding one or more polypeptides for delivery and expression in a host (e.g., a mammal such as a mouse, rat, guinea pig, hamster, cat, dog, rabbit, pig, cow, horse, or primate (e.g., human)).
[0086] The vector may include one or more marker genes that allow selection of a transformed host or a transfected host. Marker genes include biocide resistance, such as resistance to antibiotics, heavy metals, etc., providing complementation of prototrophy in auxotrophic hosts, etc. Suitable marker genes for expression vectors of the present invention include, for example, neomycin / G418 resistance genes, hygromycin resistance genes, histidinol resistance genes, tetracycline resistance genes, and ampicillin resistance genes.
[0087] The vector may further comprise a regulatory sequence that allows one or more of transcription, translation and expression of the nucleic acid contained in the vector in a cell transfected with the vector or infected with a virus comprising the vector. As used herein, "operably linked" sequences include regulatory sequences that are adjacent to the nucleotide sequence encoding the constitutively active TFEB polypeptide and regulatory sequences that act in trans or at a distance to control the nucleotide sequence encoding the constitutively active TFEB polypeptide.
[0088] Regulatory sequences may include appropriate transcription initiation sequences, termination sequences, promoter sequences, and enhancer sequences; RNA processing signals, such as splicing and polyadenylation (polyA) signal sequences; sequences that stabilize cytoplasmic mRNA; sequences that increase translation efficiency (i.e., Kozak consensus sequences); sequences that enhance protein stability; and sequences that enhance secretion of the encoded product, when desired. The polyA signal sequence may be synthetic or may be derived from a variety of suitable species, including, for example, SV-40, humans, and cattle.
[0089] When the vector is used for administration to a host (e.g., a human), the vector (e.g., AAV) preferably has a low replication efficiency in the target cell (e.g., producing no more than about 1 progeny per cell, or more preferably no more than 0.1 progeny per cell). The replication efficiency can be easily determined empirically by measuring the viral titer after infecting the target cell.
[0090] The polypeptide, nucleic acid or vector can be formulated into a composition (e.g., a pharmaceutical composition) comprising the polypeptide, nucleic acid or vector and a carrier (e.g., a pharmaceutically or physiologically acceptable carrier). In addition, the polypeptide, nucleic acid, vector or composition of the present invention can be used alone or as a part of a pharmaceutical preparation for the methods described herein.
[0091] A composition (e.g., a pharmaceutical composition) may comprise more than one polypeptide, nucleic acid, vector or composition of the invention. Alternatively or additionally, the composition may comprise one or more other pharmaceutically active agents or drugs. Examples of such other pharmaceutically active agents or drugs that may be suitable for use in the pharmaceutical composition include lampalizumab (anti-complement factor D; Genentech) for patients with geographic atrophy secondary to AMD; brolicizumab (pan-isotype anti-VEGF-A; Novartis) for wet AMD; OPT-302 (soluble VEGF-C / D receptor; Ophthea) for wet AMD and diabetic retinal edema (DME); PanOptica topical VEGF inhibitor for wet AMD; optionally with LUCENTIS TM (ranibizumab injection) combined with pegpleranib (DNA aptamer that binds to PDGF isoforms; Ophtotech / Novartis); rinucumab (anti-PDGF receptor; Regeneron), optionally with EYLEA TM(aflibercept); DE-120 (anti-PDGF / VEGF bispecific; Santen); vorolanib (an oral RTK inhibitor that inhibits the kinase activity of pDGF and VEGF; Tyrogenex); nevacumab (anti-angiopoietin 2; Regeneron), optionally with EYLEA TM (aflibercept); RG-7716 (anti-angiopoietin 2 / VEGF bispecific; Chugai); ARP-1536 (anti-VE PTP; Akebia / Aeripo); ICON-1 (chimeric protein binding to tissue factor; Iconic Therapeutic); and carotuximab (anti-endogin; Tracon / Santen).
[0092] The carrier can be any conventionally used carrier and is limited only by physicochemical considerations (e.g., solubility and lack of reactivity with the active compound) and the route of administration. Pharmaceutically acceptable carriers such as vehicles, adjuvants, excipients, and diluents described herein are well known to those skilled in the art and are readily available to the public. Preferably, a pharmaceutically acceptable carrier is one that is chemically inert to the active agent and one that has no deleterious side effects or toxicity under the conditions of use.
[0093] The choice of carrier will be determined in part by the particular polypeptide, nucleic acid, vector or composition thereof of the invention and other active agents or drugs being used, as well as the particular method used to administer the polypeptide, nucleic acid, vector or composition thereof.
[0094] Polypeptide, nucleic acid, vector or its composition can be applied to the subject by any method.For example, polypeptide, nucleic acid encoding the polypeptide or vector comprising the nucleic acid can be introduced into cells (for example, in subjects) by any of a variety of techniques, for example, by contacting the cells with nucleic acid or vector as a part of the construct, as described herein, which can deliver and express nucleic acid.Specific protocols for introducing and expressing nucleic acids in cells are known in the art.
[0095] Any suitable dose of a polypeptide, nucleic acid, vector, or combination thereof may be administered to a subject. The appropriate dose will vary according to factors such as the subject's age, weight, height, sex, general medical condition, previous medical history, and disease progression, and may be determined by a clinician. The amount or dose should be sufficient to affect a desired biological response, such as a therapeutic or preventive response, in a clinically reasonable time frame in the subject.
[0096] For example, the polypeptide can be administered at a dose of about 0.05 mg to about 10 mg (e.g., 0.1 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg and ranges thereof) per inoculation of a host (e.g., a mammal, e.g., a human) and preferably about 0.1 mg to about 5 mg per inoculation. Several doses (e.g., 1, 2, 3, 4, 5, 6 or more doses) can be provided (e.g., over a period of weeks or months).
[0097] The dosing period can be appropriately determined according to the progress of treatment. In an embodiment, the dosing period can include less than one year, less than 9 months, less than 8 months, less than 7 months, less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months or one month. In other embodiments, during the length of the dosing period, the dosing period can include three dosings per day, twice dosing per day, or once dosing per day.
[0098] When the vector is a viral vector, a suitable dose may include about 1×10 5 About 1×10 12 (For example, 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 and ranges thereof) plaque forming units (pfu), although lower or higher doses may be administered to the host.
[0099] Polypeptide, nucleic acid, carrier or its composition can be applied to the subject by various approaches, including but not limited to topical, subcutaneous, intramuscular, intradermal, intraperitoneal, intrathecal, intravenous, subretinal injection and intravitreal injection. In one embodiment, polypeptide, nucleic acid, carrier or composition can be directly injected into the eye via subretinal or intraretinal injection or directly applied (e.g., topical application) by topical application (e.g., as eye drops). When multiple administrations are performed, administration can be performed at one or more positions of the subject, and a single dose can be administered by dividing a single dose into equal parts for use in one, two, three, four or more positions of an individual.
[0100] The administration of polypeptide, nucleic acid, carrier or its composition can be "preventive" or "therapeutic". When provided preventively, polypeptide, nucleic acid, carrier or its composition is provided before the subject is diagnosed as AMD, neurodegenerative disease, DR and / or DME. For example, the subject with the risk of developing AMD, neurodegenerative disease, DR and / or DME is a group of patients preferably treated preventively. The preventive administration of polypeptide, nucleic acid, carrier or its composition can prevent, improve or delay AMD, neurodegenerative disease, DR and / or DME. When provided therapeutically, polypeptide, nucleic acid, carrier or its composition is provided when or after diagnosing AMD, neurodegenerative disease, DR and / or DME.
[0101] When the subject has been diagnosed with AMD, a neurodegenerative disease, DR or DME, the polypeptide, nucleic acid, vector or composition thereof can be administered in combination with other therapeutic treatments, such as lambalizumab (anti-complement factor D; Genentech); benralizumab (pan-isotype anti-VEGF-A; Novartis); OPT-302 (soluble VEGF-C / D receptor; Ophthea); PanOptica topical VEGF inhibitor; pegpleranib (DNA aptamer that binds to PDGF isoforms; Ophtotech / Novartis); LUCENTIS TM (ranibizumab injection); linusumab (anti-PDGF receptor; Regeneron); EYLEA TM (aflibercept); DE-120 (anti-PDGF / VEGF bispecific; Santen); vorolanib (an oral RTK inhibitor that inhibits the kinase activity of pDGF and VEGF; Tyrogenex); nevacumab (anti-angiopoietin 2; Regeneron); RG-7716 (anti-angiopoietin 2 / VEGF bispecific; Chugai); ARP-1536 (anti-VE PTP; Akebia / Aeripo); ICON-1 (a chimeric protein that binds to tissue factor; Iconic Therapeutic); and carlotuximab (anti-endogin; Tracon / Santen).
[0102] As used herein, the terms "treating" and "prevention" do not necessarily mean 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention that one of ordinary skill in the art would recognize as having a potential benefit or therapeutic effect.
[0103] There are multiple suitable preparations for the pharmaceutical composition of the inventive method. Any suitable carrier can be used in the context of the present invention, and such carrier is well known in the art. The selection of carrier will be determined in part by the specific part (e.g., eye cell, RPE cell, photoreceptor cell, rod cell and cone cell) to which the composition will be applied and the ad hoc method for applying the composition. The pharmaceutical composition can optionally be sterile or sterile except one or more adeno-associated virus vectors.
[0104] Suitable formulations for pharmaceutical compositions include aqueous and non-aqueous solutions, isotonic sterile solutions that may contain antioxidants, buffers and antibacterial agents, and aqueous and non-aqueous sterile suspensions that may contain suspending agents, solubilizers, thickeners, stabilizers and preservatives. The formulations may be present in sealed containers, such as ampoules and vials, in unit dose or multi-dose form, and may be stored under freeze-dried (lyophilized) conditions, requiring only the addition of sterile liquid carriers, such as water for injection, just before use. Extemporaneous solutions and suspensions may be prepared from sterile powders, granules and tablets. Preferably, the carrier is a buffered saline solution. More preferably, the pharmaceutical composition for the method of the present invention is formulated to protect polypeptides, nucleic acids or carriers from damage before administration. For example, the pharmaceutical composition may be formulated to reduce the loss of polypeptides, nucleic acids or carriers in devices such as glassware, syringes or needles for preparing, storing or administering polypeptides, nucleic acids or carriers. The pharmaceutical composition may be formulated to reduce the light sensitivity and / or temperature sensitivity of polypeptides, nucleic acids or carriers. To this end, the pharmaceutical composition preferably comprises a pharmaceutically acceptable liquid carrier, such as, for example, those described above, and a stabilizer selected from the group consisting of polysorbate 80, L-arginine, polyvinyl pyrrolidone, trehalose, and combinations thereof. Use of such compositions can extend the shelf life of polypeptides, nucleic acids, or vectors, facilitate administration, and improve the efficiency of the methods of the present invention.
[0105] The pharmaceutical composition may also be formulated to enhance the transduction / transfection efficiency of the polypeptide, nucleic acid or vector. In addition, one of ordinary skill in the art will appreciate that the pharmaceutical composition may contain other therapeutic agents or bioactive agents.
[0106] The following implementation methods are described by way of example:
[0107] Embodiment 1. A method for restoring lysosomal function in retinal pigment epithelial (RPE) cells, comprising administering to a subject in need thereof (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of transcription factor EB (TFEB) or (ii) the polypeptide.
[0108] Embodiment 2. The method of embodiment 1, wherein the subject has age-related macular degeneration (AMD) or is at risk of developing AMD.
[0109] Embodiment 3. The method of embodiment 2, wherein the AMD is atrophic AMD, optionally wherein the atrophic AMD comprises geographic atrophy.
[0110] Embodiment 4. The method of embodiment 2, wherein the AMD is wet AMD.
[0111] Embodiment 5. The method of embodiment 1, wherein the subject has or is at risk of developing Stargardt's macular retinal degeneration.
[0112] Embodiment 6. The method of embodiment 1, wherein the subject suffers from or is at risk of developing a neurodegenerative disease.
[0113] Embodiment 7. The method according to embodiment 6, wherein the neurodegenerative disease is Alzheimer's disease or Parkinson's disease.
[0114] Embodiment 8. The method of embodiment 1, wherein the subject suffers from diabetic retinopathy (DR) or is at risk of developing DR.
[0115] Embodiment 9. A method for preventing and / or treating age-related macular degeneration (AMD), Stargardt macular retinal degeneration, neurodegenerative diseases or diabetic retinopathy in a subject, comprising administering to the subject (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of transcription factor EB (TFEB) or (ii) the polypeptide.
[0116] Embodiment 10. The method of embodiment 9, wherein the AMD is atrophic AMD, optionally wherein the atrophic AMD comprises geographic atrophy.
[0117] Embodiment 11. The method of embodiment 9, wherein the AMD is wet AMD.
[0118] Embodiment 12. The method of embodiment 9, wherein the neurodegenerative disease is Alzheimer's disease or Parkinson's disease.
[0119] Embodiment 13. The method of any one of embodiments 1 to 12, wherein the nucleic acid further comprises an hVMD2 promoter.
[0120] Embodiment 14. The method of any one of embodiments 1 to 13, wherein the nucleic acid is contained in a vector.
[0121] Embodiment 15. A method according to embodiment 14, wherein the vector is an adeno-associated virus (AAV) vector.
[0122] Embodiment 16. A method according to embodiment 15, wherein the AAV vector is AAV2.
[0123] Embodiment 17. A method according to any one of embodiments 1 to 16, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1, except that the serine at one or more of positions 138, 142, 211, 455, 462, 463, 466, 467 and 469 of SEQ ID NO:1 is independently substituted by another amino acid.
[0124] Embodiment 18. The method according to embodiment 17, wherein the serine at position 138 of SEQ ID NO: 1 is substituted with alanine.
[0125] Embodiment 19. The method according to embodiment 17 or 18, wherein the serine at position 142 of SEQ ID NO: 1 is substituted with alanine.
[0126] Embodiment 20. The method according to any one of embodiments 17 to 19, wherein the serine at position 211 of SEQ ID NO: 1 is substituted with alanine.
[0127] Embodiment 21. The method according to any one of embodiments 17 to 20, wherein the serine at position 455 of SEQ ID NO: 1 is substituted with alanine.
[0128] Embodiment 22. The method according to any one of embodiments 17 to 21, wherein the serine at position 462 of SEQ ID NO: 1 is substituted with aspartic acid.
[0129] Embodiment 23. The method according to any one of embodiments 17 to 22, wherein the serine at position 463 of SEQ ID NO: 1 is substituted with aspartic acid.
[0130] Embodiment 24. The method of any one of embodiments 17 to 23, wherein the serine at position 466 of SEQ ID NO: 1 is substituted with aspartic acid.
[0131] Embodiment 25. The method according to any one of embodiments 17 to 24, wherein the serine at position 467 of SEQ ID NO: 1 is substituted with alanine.
[0132] Embodiment 26. The method according to any one of embodiments 17 to 25, wherein the serine at position 469 of SEQ ID NO: 1 is substituted with aspartic acid.
[0133] Embodiment 27. A method according to any one of embodiments 1 to 26, wherein the subject is human.
[0134] Embodiment 28. The method of any one of embodiments 1 to 27, wherein the nucleic acid, the polypeptide, or a vector comprising the nucleic acid is administered by subretinal injection, intravitreal injection, or topical administration.
[0135] Embodiment 29. A polypeptide comprising the amino acid sequence of SEQ ID NO: 1, except that the serine at each of positions 138, 142, and 211 of SEQ ID NO: 1 is substituted with alanine, respectively.
[0136] Embodiment 30. A polypeptide comprising the amino acid sequence of SEQ ID NO: 1, except that the serine at position 455 of SEQ ID NO: 1 is substituted with alanine, and optionally, the serine at position 211 of SEQ ID NO: 1 is substituted with alanine.
[0137] Embodiment 31. A polypeptide comprising the amino acid sequence of SEQ ID NO: 1, except that the serine at each of positions 462, 463, 466 and 469 of SEQ ID NO: 1 is substituted with aspartic acid, respectively, and the serine at position 467 of SEQ ID NO: 1 is substituted with alanine.
[0138] Embodiment 32. A nucleic acid encoding a polypeptide according to any one of embodiments 29 to 31.
[0139] Embodiment 33. A vector comprising the nucleic acid according to embodiment 32.
[0140] Embodiment 34. A pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier and (b) a polypeptide according to any one of embodiments 29 to 31, a nucleic acid encoding the polypeptide, or a vector comprising the nucleic acid.
[0141] The following examples further illustrate the present invention but, of course, should not be construed as limiting the scope of the present invention in any way.
[0142] Example
[0143] This example demonstrates that administration of constitutively active TFEB can alleviate alterations in lysosomal function and autophagy in RPE cells, thereby suppressing AMD-like phenotypes.
[0144] Cryba1 knockout and conditional knockout mice (see Figures 11-18)
[0145] Cryba1 (encoding βA3 / A1-crystallin) knockout mice (KO) and conditional knockout (cKO) are mouse models with AMD-like pathology. βA3 / A1-crystallins are located in the lysosomal lumen. In Cryba1 KO or cKO mice, RPE cell abnormalities develop as follows: abnormal ERM phosphorylation and Rho-GTPase expression (2-3 weeks); microvilli destruction (1 month); RPE heterogeneity, microvilli loss, mismatching (mistrafficking) and EMT (3-4 months); and severe phenotype (9 months) (see Figure 15C).
[0146] Cryba1 cKO mice have reduced expression of proteins in the endocytic pathway in RPE cells (such as Rab5, EEA1, and AAPL1), reduced expression of apical proteins in RPE cells (such as ERM and EBP50), and altered clathrin-mediated endocytosis in RPE cells (see Figure 2A -B, 3A-C, and 4). Cryba1 cKO mice exhibited increased iron accumulation and inflammasome activation in RPE cells ( Fig. 8A In addition, Cryba1 cKO mice had reduced expression of CLEAR (Coordinated Lysosomal Expression and Regulation) network genes, increased lysosomal pH, reduced cathepsin D enzymatic activity, loss of cobblestone-like structures, and reduced expression of RPE65 in RPE cells (see Fig.11A -B, 12A-B, 13A-B, 14A-B and 17A).
[0147] Furthermore, TFEB activation is abnormal in RPE cells of human AMD patients and in RPE cells of Cryba1 KO mice (see Figures 1A-1C and 11A-11B).
[0148] Production of AAV vectors carrying wild-type and constitutively active TFEB
[0149] To determine whether the AMD-like phenotype of Cryba1 cKO mice could be rescued by constitutively activated TFEB, AAV vectors carrying wild-type (WT) and constitutively active TFEB-S210A were engineered, as described in Figure 5 shown.
[0150] First WT TFEB was cloned into pCR-Blunt vector (Invitrogen, Carlsbad, CA). In brief, RNA was extracted from mouse kidneys and then reverse transcribed to generate cDNA. A set of primers (CCDS 28856.1, TFEB_CDS_F:ATGGCGTCACGCATCGGG (SEQ ID NO:2) and TFEB_CDS_R:TCACAGAACATCACCCTCCT (SEQ ID NO:3)) and high-fidelity polymerase (Thermo Scientific, Waltham, MA) were used to amplify WT TFEB by PCR. According to the manufacturer's instructions (confirmed by sequencing), the PCR product was gel purified and connected to the pCR-Blunt vector.
[0151] Alignment of human and mouse TFEB proteins revealed 93.5% identity in 476 overlapping residues corresponding to a shorter annotation of mouse TFEB (CCDS 50133.1). Of note, in mouse, there is a loss of a glutamine residue at position 44, so that the serine position critical for the regulation of nuclear localization of TFEB is moved to position 210 in mouse compared to position 211 in humans.
[0152] To generate the TFEB-S210A mutant, the TCC codon was mutated to GCC by introducing a point T->G mutation into WT TFEB in pCR-Blunt using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA) according to the manufacturer's instructions (confirmed by sequencing).
[0153] To prepare plasmids for Gibson assembly, eGFP was excised using Age1 (BshT1) and Sac1 restriction enzymes, and the resulting linearized sc (self-complementary)-hVMD2 was gel purified. A shorter version of TFEB (CCDS 50133.1) was PCR amplified from WT or mutant TFEB in the pCR-Blunt vector using the following primers: sc-hVMD2_TFEB_F:accagcctagtcgccagaccaccgg GCCACCATGGCGTCACGCATCGGG (SEQ ID NO: 4) and sc-hVMD2_TFEB_R: cacagtcgaggctgatcagcgagctTCACAGAACATCACCCTCCT (SEQ ID NO: 5). Both primers contain sequences overlapping with the linearized sc-hVMD2 transfer plasmid (lowercase letters), and the forward primer contains the KOZAK sequence GCCACC , in order to improve translation efficiency.
[0154] The linearized sc-hVMD2 plasmid and newly PCR-amplified WT or TFEB-S210A were ligated using the Gibson Assembly Kit (New England Biolabs, Ipswich, MA). The integrity of the ITRs was confirmed by SmaI digestion. The sc-hVMD2-TFEB and sc-hVMD2-TFEB-S210A constructs were packaged into AAV2 and AAV8-2YF vectors using a triple transfection method in AAV-HEK-293 cells (Agilent). The virus was purified on an iodixanol gradient and the buffer was exchanged to DPBS. The virus was titered using QPCR and had a 1.64 × 10 12 vg (vector genome) / ml (WT) and 1.72×10 12 Titer of vg / ml (mutant).
[0155] Transfection of AAV-TFEB vector into RPE cells
[0156] like Figure 6 As shown in AC, subretinal injection of AAV2-TFEB-GFP showed efficient infection of more than 85-90% of RPE cells after a single subretinal infection. Therefore, the AAV-TFEB vector is suitable for transfection in RPE cells.
[0157] Infection of RPE cells from Cryba1 KO mice with an AAV vector expressing constitutively active TFEB alleviates alterations in lysosomal function and autophagy
[0158] Cryba1 KO mice were prepared as described in Valapala et al., Scientific Reports, 5:8755 (2015). S210A ) were used to infect RPE cells from Cryba1 KO mice. As a control, RPE cells from Cryba1 KO mice were infected with AAV2 vectors expressing wild-type mouse TFEB or empty vector.
[0159] like Fig. 7A -C and 10A-B , constitutively active TFEB localized to the nuclei of RPE cells in Cryba1 KO and cKO mice and reduced alterations in CLEAR network gene expression and autophagosome accumulation, respectively.
[0160] Infection of RPE cells from Cryba1 KO mice with an AAV vector expressing constitutively active TFEB reduces iron accumulation and inflammasome activation
[0161] like Fig. 8A -C, total iron and redox-sensitive ferrous iron levels were increased in RPE cells of aged Cryba1 cKO mice compared with controls. In addition, the levels of inflammasome markers NLRP3 and IL-1β were increased in RPE cells of aged Cryba1 cKO mice compared with age-matched controls. Iron overload due to lysosomal abnormalities in RPE cells can lead to inflammasome activation and cell death.
[0162] To determine whether constitutively active TFEB could rescue this phenotype, mice expressing a constitutively active form of TFEB (TFEB) were cultured in the presence of the iron chelator LCN-2 and the iron source FAC. S210A ) were used to infect RPE cells from Cryba1 KO mice. As a control, RPE cells from Cryba1 KO mice were infected with AAV vectors expressing wild-type mouse TFEB in the presence of iron chelator LCN-2 and iron source FAC.
[0163] Iron accumulation and inflammasome activation (increased NKRP3 and IL-1β expression) were reversed in Cryba1 KO RPE cells infected with mutant TFEB vectors compared with cells infected with control (WT) TFEB vectors (see Fig. 9A -C).
[0164] Thus, administration of constitutively active TFEB alleviated alterations in lysosomal function and autophagy in RPE cells, supporting the use of constitutively active TFEB in treating or preventing disorders such as AMD, diabetic retinopathy and diabetic macular edema, as well as neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease.
[0165] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0166] In the context of describing the present invention (especially in the context of the following claims), the use of the terms "a" and "an" and "the" and "at least one" and similar indicators should be interpreted as covering both singular and plural forms, unless otherwise indicated herein or clearly contradicted by the context. Unless otherwise indicated herein or clearly contradicted by the context, the term "at least one" (e.g., "at least one of A and B") used after a list of one or more items should be interpreted as meaning one item selected from the listed items (A or B) or any combination of two or more than two listed items (A and B). Unless otherwise indicated, the terms "comprising", "having", "including" and "containing" will be interpreted as open terms (i.e., meaning "including but not limited to"). Unless otherwise indicated herein, the reference to the range of values herein is intended only to be used as a shorthand method of individually referring to each individual value within the range, and each individual value is incorporated into the specification as if it were individually cited herein. Unless otherwise indicated herein or clearly contradicted by the context, all methods described herein can be performed in any suitable order. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the present invention and does not limit the scope of the present invention unless otherwise required. No language in the specification should be construed as indicating that any non-claimed element is essential to the practice of the present invention.
[0167] Preferred embodiments of the present invention are described herein, including the best mode of carrying out the present invention known to the inventor. After reading the foregoing description, changes in those preferred embodiments may become apparent to those of ordinary skill in the art. The inventor expects that those skilled in the art will adopt such variations as necessary, and the inventor wishes that the present invention be implemented in other ways than those specifically described herein. Therefore, the present invention includes all modifications and equivalents of the subject matter cited in the appended claims as allowed by applicable law. In addition, unless otherwise indicated herein or otherwise clearly contradictory to the content, the present invention encompasses any combination of the above elements with all possible variations thereof. Sequence Listing <110> Federal System of Higher Education - University of Pittsburgh (University of Pittsburgh - Of the Commonwealth System of Higher Education <120> Methods for restoring lysosomal function in retinal pigment epithelial cells by activating TFEB <130> 748077 <150> US 62 / 897,800 <151> 2019-09-09 <160> 5 <170> PatentIn version 3.5 <210> 1 <211> 476 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 1 Met Ala Ser Arg Ile Gly Leu Arg Met Gln Leu Met Arg Glu Gln Ala 1 5 10 15 Gln Gln Glu Glu Gln Arg Glu Arg Met Gln Gln Gln Ala Val Met His 20 25 30 Tyr Met Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Leu Gly Gly Pro 35 40 45 Pro Thr Pro Ala Ile Asn Thr Pro Val His Phe Gln Ser Pro Pro Pro 50 55 60 Val Pro Gly Glu Val Leu Lys Val Gln Ser Tyr Leu Glu Asn Pro Thr 65 70 75 80 Ser Tyr His Leu Gln Gln Ser Gln His Gln Lys Val Arg Glu Tyr Leu 85 90 95 Ser Glu Thr Tyr Gly Asn Lys Phe Ala Ala His Ile Ser Pro Ala Gln 100 105 110 Gly Ser Pro Lys Pro Pro Pro Ala Ala Ser Pro Gly Val Arg Ala Gly 115 120 125 His Val Leu Ser Ser Ser Ala Gly Asn Ser Ala Pro Asn Ser Pro Met 130 135 140 Ala Met Leu His Ile Gly Ser Asn Pro Glu Arg Glu Leu Asp Asp Val 145 150 155 160 Ile Asp Asn Ile Met Arg Leu Asp Asp Val Leu Gly Tyr Ile Asn Pro 165 170 175 Glu Met Gln Met Pro Asn Thr Leu Pro Leu Ser Ser Ser His Leu Asn 180 185 190 Val Tyr Ser Ser Asp Pro Gln Val Thr Ala Ser Leu Val Gly Val Thr 195 200 205 Ser Ser Ser Cys Pro Ala Asp Leu Thr Gln Lys Arg Glu Leu Thr Asp 210 215 220 Ala Glu Ser Arg Ala Leu Ala Lys Glu Arg Gln Lys Lys Asp Asn His 225 230 235 240 Asn Leu Ile Glu Arg Arg Arg Arg Phe Asn Ile Asn Asp Arg Ile Lys 245 250 255 Glu Leu Gly Met Leu Ile Pro Lys Ala Asn Asp Leu Asp Val Arg Trp 260 265 270 Asn Lys Gly Thr Ile Leu Lys Ala Ser Val Asp Tyr Ile Arg Arg Met 275 280 285 Gln Lys Asp Leu Gln Lys Ser Arg Glu Leu Glu Asn His Ser Arg Arg 290 295 300 Leu Glu Met Thr Asn Lys Gln Leu Trp Leu Arg Ile Gln Glu Leu Glu 305 310 315 320 Met Gln Ala Arg Val His Gly Leu Pro Thr Thr Ser Pro Ser Gly Met 325 330 335 Asn Met Ala Glu Leu Ala Gln Gln Val Val Lys Gln Glu Leu Pro Ser 340 345 350 Glu Glu Gly Pro Gly Glu Ala Leu Met Leu Gly Ala Glu Val Pro Asp 355 360 365 Pro Glu Pro Leu Pro Ala Leu Pro Pro Gln Ala Pro Leu Pro Leu Pro 370 375 380 Thr Gln Pro Pro Ser Pro Phe His His Leu Asp Phe Ser His Ser Leu 385 390 395 400 Ser Phe Gly Gly Arg Glu Asp Glu Gly Pro Pro Gly Tyr Pro Glu Pro 405 410 415 Leu Ala Pro Gly His Gly Ser Pro Phe Pro Ser Leu Ser Lys Lys Asp 420 425 430 Leu Asp Leu Met Leu Leu Asp Asp Ser Leu Leu Pro Leu Ala Ser Asp 435 440 445 Pro Leu Leu Ser Thr Met Ser Pro Glu Ala Ser Lys Ala Ser Ser Arg 450 455 460 Arg Ser Ser Phe Ser Met Glu Glu Gly Asp Val Leu 465 470 475 <210> 2 <211> 18 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 2 atggcgtcac gcatcggg 18 <210> 3 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 3 tcacagaaca tcaccctcct 20 <210> 4 <211> 49 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 4 accagcctag tcgccagacc accgggccac catggcgtca cgcatcggg 49 <210> 5 <211> 45 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 5 cacagtcgag gctgatcagc gagcttcaca gaacatcacc ctcct 45
Claims
1. (i) a nucleic acid encoding a polypeptide comprising a constitutively active form of transcription factor EB (TFEB) or (ii) use of said polypeptide in the manufacture of a medicament for preventing and / or treating age-related macular degeneration (AMD), Stargardt macular retinal degeneration or diabetic retinopathy in a subject, The polypeptide consists of the amino acid sequence of SEQ ID NO:1 with one or more of the following amino acid substitutions: (i) the serine at position 467 of SEQ ID NO: 1 is substituted with alanine; as well as (ii) The serine at position 211 of SEQ ID NO: 1 is substituted with alanine.
2. The use according to claim 1, wherein the AMD is atrophic AMD, optionally wherein the atrophic AMD comprises geographic atrophy.
3. The use according to claim 1, wherein the AMD is wet AMD.
4. The use according to any one of claims 1 to 3, wherein the nucleic acid further comprises a hVMD2 promoter.
5. The method according to any one of claims 1 to 3, wherein the nucleic acid is contained in a vector.
6. The use according to claim 5, wherein the vector is an adeno-associated virus (AAV) vector.
7. The use according to claim 6, wherein the AAV vector is AAV2.
8. The use according to claim 1, wherein the serine at position 211 of SEQ ID NO: 1 is substituted with alanine.
9. The use according to claim 1, wherein the serine at position 467 of SEQ ID NO: 1 is substituted with alanine.
10. The use according to any one of claims 1 to 3, wherein the subject is a human.
11. The use according to any one of claims 1 to 3, wherein the nucleic acid, the polypeptide or a vector comprising the nucleic acid is formulated to be administered by subretinal injection, intravitreal injection or topical administration.
